BioXcel Therapeutics Inc (NASDAQ: BTAI) kicked off on Monday, down -7.32% from the previous trading day, before settling in for the closing price of $2.05. Over the past 52 weeks, BTAI has traded in a range of $1.17-$12.16.
A company in the Healthcare sector has jumped its sales by 6.20% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 75.50%. With a float of $18.89 million, this company’s outstanding shares have now reached $19.65 million.
BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 3.84%, while institutional ownership is 8.53%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -5.12 earnings per share (EPS), higher than consensus estimate (set at -7.68) by 2.56. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 55.44% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Take a look at BioXcel Therapeutics Inc’s (BTAI) current performance indicators. Last quarter, stock had a quick ratio of 0.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 42.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.67, a number that is poised to hit -1.34 in the next quarter and is forecasted to reach -3.67 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was inferior than the volume of 4.48 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.45%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 8.85%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.92, while its 200-day Moving Average is $2.60. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $1.97. Second resistance stands at $2.03. The third major resistance level sits at $2.07. If the price goes on to break the first support level at $1.87, it is likely to go to the next support level at $1.83. The third support level lies at $1.77 if the price breaches the second support level.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
The company with the Market Capitalisation of 37.33 million has total of 16,009K Shares Outstanding. Its annual sales at the moment are 2,270 K in contrast with the sum of -59,600 K annual income. Company’s last quarter sales were recorded 120 K and last quarter income was -19,190 K.
